ClinicalTrials.gg
WithdrawnNCT07307768Updated Oct 19, 2026

Ketamine Biomarker Validation

A Phase 1 interventional study of Ketamine (0.25 mg/kg) and Ketamine (0.5 mg/kg) in Treatment Resistant Depression (TRD), sponsored by Soterix Medical. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Soterix Medical · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Funding was not provided
Updated Oct 19, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing ketamine in Depressive Disorder, Treatment-Resistant — 8 open to participants now, 11 under way, 3 of them phase 3. Ketamine · Depressive Disorder, Treatment-Resistant.

Enrollment
40th of 42
0 · median 35
Started
2025
with 2 others
Phase 1
7 of 42
1 open now
Registered
40th of 42
by date

Among the 42 studies testing ketamine in Depressive Disorder, Treatment-Resistant, this one is the 40th largest by enrollment, is one of 3 that started in 2025, is one of 7 in phase 1, and was the 40th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

8 of the 42 studies testing ketamine in Depressive Disorder, Treatment-Resistant are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing ketamine in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

An EEG-based biomarker will be developed for the effects of ketamine infusion in patients with Depression. The effects of ketamine infusion on Depression symptoms and EEG signals will be analyzed.

Read the detailed description

This trial is a biomarker development study. The effects of various doses of ketamine infusion on depressive symptoms and EEG signals in patients with unipolar depression will be analyzed.

03

Conditions studied

  • Treatment Resistant Depression (TRD)

Keywords

  • Ketamine
  • EEG
  • Depression
  • MDD
  • unipolar Depression
  • Biomarker
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physically healthy patients who meet DMS-5 criteria for a major depressive episode (MDE) in the context of MDD and who score at least 22 on the Montgomery-Åsberg Depression Rating Scale (MADRS)
  • If taking antidepressants, dose is stable for at least 6 weeks.

Exclusion criteria

Exclusion Criteria:

  • Lifetime history of bipolar disorder, schizoaffective disorder, schizophrenia, or any other psychotic disorder, including MDD with psychotic features
  • A first-degree relative with bipolar disorder, schizoaffective disorder, or schizophrenia, with the potential participant younger than 33 years (i.e., still at age of risk for a psychotic disorder)
  • Receipt of electroconvulsive therapy within 3 months of enrolling in the study
  • History of IV drug use
  • Nonresponse or intolerance to ketamine administered either clinically or as part of a prior research study
  • Pregnancy, planning to conceive, or sexually active but not using adequate .
  • Actively suicidal (CSSRS≥3)
  • No antipsychotics or medications (e.g. benzodiazepines, anti-epileptics) that are likely to interact with GABA or glutamate,
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Low level ketamine

    0.25 mg/kg ketamine infusion

    Drug: Ketamine (0.25 mg/kg)

  • Experimental
    Medium level ketamine

    0.5 mg/kg ketamine infusion

    Drug: Ketamine (0.5 mg/kg)

  • Experimental
    High level ketamine

    0.75 mg/kg ketamine infusion

    Drug: Ketamine (0.75 mg/kg)

Interventions

  • DrugKetamine (0.25 mg/kg)

    Drug page: Ketamine

    Low level ketamine infusion therapy.

  • DrugKetamine (0.5 mg/kg)

    Drug page: Ketamine

    Medium level ketamine infusion therapy.

  • DrugKetamine (0.75 mg/kg)

    Drug page: Ketamine

    High level ketamine infusion therapy.

06

What researchers measure

Primary outcomes

  1. Hamilton Depression Rating Scale (HDRS) 22

    Twenty-two question Depression rating scale (excluding the two questions on weight loss and diurnal variation)

    Time frame: Baseline, Hour 1, Hour 4, Hour 24, and Hour 72

Secondary outcomes

  1. The Columbia Suicidality Severity Rating Scale (C-SSRS)

    A semi-structured, investigator-rated interview assessing both suicidal behavior and suicidal ideation.

    Time frame: Baseline, Hour 1, Hour 4, Hour 24, and Hour 72

  2. The Clinician Administered Dissociative States Scale (CADSS)

    A scale that rates dissociative symptoms with a 27-item scale, rated 0-4, 19 subjective, and 8 observer items

    Time frame: Baseline, and Hour 1

  3. Montgomery-Asberg Depression Rating Scale (MADRS)

    A ten-item diagnostic used for the assessment of depression severity

    Time frame: Baseline and Hour 24

07

Study locations

1 site
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2027, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 29, 2025
StartEst.
Dec 20, 2025
Primary completionEst.
Dec 1, 2027
CompletionEst.
Mar 1, 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Funding was not provided
changed Oct 19, 2026
Enrollment
20 (estimated)→0 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Not yet recruiting→Withdrawn
    Why stopped Funding was not provided
    Enrollment 20 (estimated)→0 (actual)
    + 2 other changes: description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07307768
Lead sponsor
Soterix Medical
Collaborators
Columbia University
Responsible party
Sponsor
First posted
Dec 29, 2025
Start date
Dec 20, 2025 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion